Thermo Fisher Scientific Stock Earnings Reports

Thermo Fisher reported a strong start to 2026: Q1 revenue grew 6% to $11.01B, adjusted operating income grew 6% to $2.4B, adjusted operating margin was 21.8%, and adjusted EPS was $5.44 (up 6%). Organic revenue was ~1% in Q1 (one fewer selling day reduced reported organic growth by ~1 point). Management closed the Clario acquisition in late March (Clario added ~$30M revenue and ~$0.01 EPS in Q1), and raised full‑year guidance: revenue now $47.3B–$48.1B (6%–8% reported growth; 3%–4% organic) and adjusted EPS $24.64–$25.12 (8%–10% growth). Key growth drivers: pharma & biotech (notably bioproduction and clinical research), Life Sciences Solutions strength, and ongoing product innovation (e.g., Glacios 3 Cryo-TEM, TSQ Certis, Gibco CTS Compleo). Capital deployment: $3B share repurchases in Q1 and a 10% dividend increase; Clario acquisition financed (~$9B purchase price plus potential earnouts). Cash/Balance Sheet: Q1 cash $3.3B, total debt $43.2B, gross leverage ~3.8x EBITDA (net ~3.5x). Management flagged headwinds from tariffs (~80 bps margin impact in Q1) and a placeholder for potential higher inflation later in the year, but emphasized strong operational productivity (PPI Business System), ongoing cost/productivity actions, AI and strategic collaborations (NVIDIA, SHL), and confidence in hitting the raised guidance. Risks called out: geopolitical uncertainty (Middle East), inflation/transportation cost volatility, and softer academic/government demand (notably in U.S. and China) affecting Analytical Instruments and A&G end markets.